Ten years of dengue drug discovery: Progress and prospects

Antiviral Research

Volumn 100, Issue 2, 2013, Pages 500-519

  Lim, Siew Pheng ^a   Wang, Qing Yin ^a   Noble, Christian G ^a   Chen, Yen Liang ^a   Dong, Hongping ^a   Zou, Bin ^a   Yokokawa, Fumiaki ^a   Nilar, Shahul ^a   Smith, Paul ^a   Beer, David ^a   Lescar, Julien ^b   Shi, Pei Yong ^a  

^a NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Antiviral; Dengue virus; Drug discovery; Flavivirus

Indexed keywords

1OAN 1; 4' AZIDOCYTIDINE; ALEXIDINE; ANTIVIRUS AGENT; ARD P0006; ARDP 0006; BALAPIRAVIR; BENZETHONIUM CHLORIDE; BI 207127; BP 2109; CASTANOSPERMINE 6 BUTYRATE; CLEMIZOLE; DN 59; ENFUVIRTIDE; FILIBUVIR; IVERMECTIN; LCTA 949; LOMIBUVIR; MARAVIROC; MYRCLUDEX B; NITD 008; NITD 618; RIBAVIRIN; SA 17; SELAMECTIN; SETROBUVIR; ST 148; ST 610; TEGOBUVIR; TENOFOVIR; TIPRANAVIR; TYROTHRICIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ERBIUM; METHYLTRANSFERASE; PROTEINASE INHIBITOR; TITANIUM;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DISSOCIATION CONSTANT; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; ENDOCYTOSIS; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SPECIFICITY; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS C; HIGH THROUGHPUT SCREENING; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IC 50; LIPID BILAYER; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN RNA BINDING; REVIEW; SHELF LIFE; STRUCTURE ACTIVITY RELATION; VIRUS ENTRY; VIRUS GENOME; VIRUS LIKE AGENT; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; DAA; DENGUE HEMORRHAGIC FEVER/DENGUE SHOCK SYNDROME; DENGUE VIRUS; DHF/DSS; DIRECT ANTIVIRAL AGENT; DRUG DEVELOPMENT; DRUG EFFECT; ENDOPLASMIC RETICULUM; FLAVIVIRUS; FLUORESCENCE POLARIZATION; FP; HCV; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGH-THROUGHPUT SCREENING; HISTORY; HTS; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; MTASE; NI; NNI; NON-NUCLEOSIDE INHIBITOR; NUCLEOSIDE ANALOG INHIBITORS; PI; POC; PROOF-OF-CONCEPT; RDRP; RNA-DEPENDENT RNA POLYMERASE; SAR; SCINTILLATION PROXIMITY ASSAY; SINGAPORE; SPA; TBEV; THERAPEUTIC INDEX; TICK-BORNE ENCEPHALITIS VIRUS; VESICULAR STOMATITIS VIRUS; VIROLOGY; WEEV; WEST NILE FLAVIVIRUS; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; WNV; YELLOW FEVER FLAVIVIRUS; YFV;

ANIMALIA; DENGUE VIRUS; FLAVIVIRUS; HEPATITIS C VIRUS;

ANTIVIRAL; DAA; DENGUE HEMORRHAGIC FEVER/DENGUE SHOCK SYNDROME; DENGUE VIRUS; DENV; DHF/DSS; DIRECT ANTIVIRAL AGENT; DRUG DISCOVERY; ENDOPLASMIC RETICULUM; ER; FLAVIVIRUS; FLUORESCENCE POLARIZATION; FP; HBV; HCV; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGH-THROUGHPUT SCREENING; HIV; HTS; HUMAN IMMUNODEFICIENCY VIRUS; METHYLTRANSFERASE; MTASE; NI; NNI; NON-NUCLEOSIDE INHIBITOR; NUCLEOSIDE ANALOG INHIBITORS; PI; POC; PROOF-OF-CONCEPT; PROTEASE INHIBITORS; RDRP; RNA-DEPENDENT RNA POLYMERASE; SAR; SCINTILLATION PROXIMITY ASSAY; SPA; STRUCTURE-ACTIVITY RELATIONSHIP; TBEV; THERAPEUTIC INDEX; TI; TICK-BORNE ENCEPHALITIS VIRUS; VESICULAR STOMATITIS VIRUS; VSV; WEEV; WEST NILE VIRUS; WESTERN EQUINE ENCEPHALITIS VIRUS; WNV; YELLOW FEVER VIRUS; YFV;

ANTIVIRAL AGENTS; DENGUE; DENGUE VIRUS; DRUG DISCOVERY; HISTORY, 21ST CENTURY; HUMANS; SINGAPORE;

EID: 84885567750     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.09.013     Document Type: Review

References (179)

1. M. Ackermann, and R. Padmanabhan De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase J. Biol. Chem. 276 2001 39926 39937
2. M.M. Alen, and D. Schols Dengue virus entry as target for antiviral therapy J. Trop. Med. 2012 2012 628475
3. S. Aravapalli, H. Lai, T. Teramoto, K.R. Alliston, G.H. Lushington, E.L. Ferguson, R. Padmanabhan, and W.C. Groutas Inhibitors of Dengue virus and West Nile virus proteases based on the aminobenzamide scaffold Bioorg. Med. Chem. 20 2012 4140 4148
4. M.E. Beatty, P. Beutels, M.I. Meltzer, D.S. Shepard, J. Hombach, R. Hutubessy, D. Dessis, L. Coudeville, B. Dervaux, O. Wichmann, H.S. Margolis, and J.N. Kuritsky Health economics of dengue: a systematic literature review and expert panel's assessment Am. J. Trop. Med. Hyg. 84 2011 473 488
5. S. Bhatt, P.W. Gething, O.J. Brady, J.P. Messina, A.W. Farlow, C.L. Moyes, J.M. Drake, J.S. Brownstein, A.G. Hoen, O. Sankoh, M.F. Myers, D.B. George, T. Jaenisch, G.R. Wint, C.P. Simmons, T.W. Scott, J.J. Farrar, and S.I. Hay The global distribution and burden of dengue Nature 496 2013 504 507
6. A. Blas-Garcia, J.V. Esplugues, and N. Apostolova Twenty years of HIV-1 non-nucleoside reverse transcriptase inhibitors: time to reevaluate their toxicity Curr. Med. Chem. 18 2011 2186 2195
7. C. Bodenreider, D. Beer, T.H. Keller, S. Sonntag, D. Wen, L. Yap, Y.H. Yau, S.G. Shochat, D. Huang, T. Zhou, A. Caflisch, X.C. Su, K. Ozawa, G. Otting, S.G. Vasudevan, J. Lescar, and S.P. Lim A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease Anal. Biochem. 395 2009 195 204
8. M. Bollati, K. Alvarez, R. Assenberg, C. Baronti, B. Canard, S. Cook, B. Coutard, E. Decroly, X. de Lamballerie, E.A. Gould, G. Grard, J.M. Grimes, R. Hilgenfeld, A.M. Jansson, H. Malet, E.J. Mancini, E. Mastrangelo, A. Mattevi, M. Milani, G. Moureau, J. Neyts, R.J. Owens, J. Ren, B. Selisko, S. Speroni, H. Steuber, D.I. Stuart, T. Unge, and M. Bolognesi Structure and functionality in flavivirus NS-proteins: perspectives for drug design Antiviral Res. 87 2010 125 148
9. A. Bonavia, M. Franti, E. Pusateri Keaney, K. Kuhen, M. Seepersaud, B. Radetich, J. Shao, A. Honda, J. Dewhurst, K. Balabanis, J. Monroe, K. Wolff, C. Osborne, L. Lanieri, K. Hoffmaster, J. Amin, J. Markovits, M. Broome, E. Skuba, I. Cornella-Taracido, G. Joberty, T. Bouwmeester, L. Hamann, J.A. Tallarico, R. Tommasi, T. Compton, and S.M. Bushell Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV) Proc. Natl. Acad. Sci. U.S.A. 108 2011 6739 6744
10. M. Brandl, X. Wu, M. Holper, L. Hong, Z. Jia, R. Birudaraj, M. Reddy, T. Alfredson, T. Tran, S. Larrabee, X. Hadig, K. Sarma, C. Washington, G. Hill, and D.B. Smith Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability Drug Dev. Ind. Pharm. 34 2008 683 691
11. C.M. Byrd, D. Dai, D.W. Grosenbach, A. Berhanu, K.F. Jones, K.B. Cardwell, C. Schneider, K.A. Wineinger, J.M. Page, C. Harver, E. Stavale, S. Tyavanagimatt, M.A. Stone, R. Bartenschlager, P. Scaturro, D.E. Hruby, and R. Jordan A novel inhibitor of dengue virus replication that targets the capsid protein Antimicrob. Agents Chemother. 57 2013 15 25
12. C.M. Byrd, D.W. Grosenbach, A. Berhanu, D. Dai, K.F. Jones, K.B. Cardwell, C. Schneider, G. Yang, S. Tyavanagimatt, C. Harver, K.A. Wineinger, J. Page, E. Stavale, M.A. Stone, K.P. Fuller, C. Lovejoy, J.M. Leeds, D.E. Hruby, and R. Jordan Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase Antimicrob. Agents Chemother. 57 2013 1902 1912
13. S.S. Carroll, V. Sardana, Z. Yang, A.R. Jacobs, C. Mizenko, D. Hall, L. Hill, J. Zugay-Murphy, and L.C. Kuo Only a small fraction of purified hepatitis C RNA-dependent RNA polymerase is catalytically competent: implications for viral replication and in vitro assays Biochemistry 39 2000 8243 8249
14. C.E. Cass, J.D. Young, S.A. Baldwin, M.A. Cabrita, K.A. Graham, M. Griffiths, L.L. Jennings, J.R. Mackey, A.M. Ng, M.W. Ritzel, M.F. Vickers, and S.Y. Yao Nucleoside transporters of mammalian cells Pharm. Biotechnol. 12 1999 313 352
15. V. Cento, C. Mirabelli, R. Salpini, S. Dimonte, A. Artese, G. Costa, F. Mercurio, V. Svicher, L. Parrotta, A. Bertoli, M. Ciotti, D. Di Paolo, C. Sarrecchia, M. Andreoni, S. Alcaro, M. Angelico, C.F. Perno, and F. Ceccherini-Silberstein HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors PLoS One 7 2012 e39652
16. Y.L. Chen, Z. Yin, J. Duraiswamy, W. Schul, C.C. Lim, B. Liu, H.Y. Xu, M. Qing, A. Yip, G. Wang, W.L. Chan, H.P. Tan, M. Lo, S. Liung, R.R. Kondreddi, R. Rao, H. Gu, H. He, T.H. Keller, and P.Y. Shi Inhibition of dengue virus RNA synthesis by an adenosine nucleoside Antimicrob. Agents Chemother. 54 2010 2932 2939
17. Y.L. Chen, Z. Yin, S.B. Lakshminarayana, M. Qing, W. Schul, J. Duraiswamy, R.R. Kondreddi, A. Goh, H.Y. Xu, A. Yip, B. Liu, M. Weaver, V. Dartois, T.H. Keller, and P.Y. Shi Inhibition of dengue virus by an ester prodrug of an adenosine analog Antimicrob. Agents Chemother. 54 2010 3255 3261
18. J.G. Christenbury, P.P. Aw, S.H. Ong, M.J. Schreiber, A. Chow, D.J. Gubler, S.G. Vasudevan, E.E. Ooi, and M.L. Hibberd A method for full genome sequencing of all four serotypes of the dengue virus J. Virol. Methods 169 2010 202 206
19. K.Y. Chung, H. Dong, A.T. Chao, P.Y. Shi, J. Lescar, and S.P. Lim Higher catalytic efficiency of N-7-methylation is responsible for processive N-7 and 2′-O methyltransferase activity in dengue virus Virology 402 2010 52 60
20. T. Cihlar, and A.S. Ray Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine Antiviral Res. 85 2010 39 58
21. J.M. Costin, E. Jenwitheesuk, S.M. Lok, E. Hunsperger, K.A. Conrads, K.A. Fontaine, C.R. Rees, M.G. Rossmann, S. Isern, R. Samudrala, and S.F. Michael Structural optimization and de novo design of dengue virus entry inhibitory peptides PLoS Negl. Trop. Dis. 4 2010 e721
22. L. Cregar-Hernandez, G.S. Jiao, A.T. Johnson, A.T. Lehrer, T.A. Wong, and S.A. Margosiak Small molecule pan-dengue and West Nile virus NS3 protease inhibitors Antiviral Chem. Chemother. 21 2011 209 217
23. S. Daffis, K.J. Szretter, J. Schriewer, J. Li, S. Youn, J. Errett, T.Y. Lin, S. Schneller, R. Zust, H. Dong, V. Thiel, G.C. Sen, V. Fensterl, W.B. Klimstra, T.C. Pierson, R.M. Buller, M. Gale Jr., P.Y. Shi, and M.S. Diamond 2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members Nature 468 2010 452 456
24. T. Dagan, C. Sable, J. Bray, and M. Gerschenson Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence? Mitochondrion 1 2002 397 412
25. T. De Burghgraeve, S.J. Kaptein, N.V. Ayala-Nunez, J.A. Mondotte, B. Pastorino, S.S. Printsevskaya, X. de Lamballerie, M. Jacobs, M. Preobrazhenskaya, A.V. Gamarnik, J.M. Smit, and J. Neyts An analogue of the antibiotic teicoplanin prevents flavivirus entry in vitro PLoS One 7 2012 e37244
26. E. De Clercq Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV Int. J. Antimicrob. Agents 33 2009 307 320
27. E. De Clercq A 40-year journey in search of selective antiviral chemotherapy Annu. Rev. Pharmacol. Toxicol. 51 2011 1 24
28. E. De Clercq, and J. Neyts Antiviral agents acting as DNA or RNA chain terminators Handb. Exp. Pharmacol. 2009 53 84
29. L. Delang, I. Vliegen, M. Froeyen, and J. Neyts Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication Antimicrob. Agents Chemother. 55 2011 4103 4113
30. J. Deng, N. Li, H. Liu, Z. Zuo, O.W. Liew, W. Xu, G. Chen, X. Tong, W. Tang, J. Zhu, J. Zuo, H. Jiang, C.G. Yang, J. Li, and W. Zhu Discovery of novel small molecule inhibitors of dengue viral NS2B-NS3 protease using virtual screening and scaffold hopping J. Med. Chem. 55 2012 6278 6293
31. M.S. Diamond, T.C. Pierson, and J.T. Roehrig Antibody therapeutics against flaviviruses Mol. Virol. Contr. Flavivir. 2012 231 256
32. H. Dong, D.C. Chang, M.H. Hua, S.P. Lim, Y.H. Chionh, F. Hia, Y.H. Lee, P. Kukkaro, S.M. Lok, P.C. Dedon, and P.Y. Shi 2′-O methylation of internal adenosine by flavivirus NS5 methyltransferase PLoS Pathog. 8 2012 e1002642
33. H. Dong, D.C. Chang, X. Xie, Y.X. Toh, K.Y. Chung, G. Zou, J. Lescar, S.P. Lim, and P.Y. Shi Biochemical and genetic characterization of dengue virus methyltransferase Virology 405 2010 568 578
34. H. Dong, B. Zhang, and P.Y. Shi Flavivirus methyltransferase: a novel antiviral target Antiviral Res. 80 2008 1 10
35. D. Durantel Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection Curr. Opin. Investig. Drugs 10 2009 860 870
36. A.P. Durbin, M.J. Vargas, K. Wanionek, S.N. Hammond, A. Gordon, C. Rocha, A. Balmaseda, and E. Harris Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever Virology 376 2008 429 435
37. M.P. Egloff, D. Benarroch, B. Selisko, J.L. Romette, and B. Canard An RNA cap (nucleoside-2′-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization EMBO J. 21 2002 2757 2768
38. S. Einav, H.D. Sobol, E. Gehrig, and J.S. Glenn The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors J. Infect. Dis. 202 2010 65 74
39. P. Erbel, N. Schiering, A. D'Arcy, M. Renatus, M. Kroemer, S. Lim, Z. Yin, T. Keller, S. Vasudevan, and U. Hommel Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus Nat. Struct. Mol. Biol. 13 2006 372 373
40. J. Fink, F. Gu, L. Ling, T. Tolfvenstam, F. Olfat, K.C. Chin, P. Aw, J. George, V.A. Kuznetsov, M. Schreiber, S.G. Vasudevan, and M.L. Hibberd Host gene expression profiling of dengue virus infection in cell lines and patients PLoS Negl. Trop. Dis. 1 2 2007 e86
41. W. Fischl, and R. Bartenschlager Exploitation of cellular pathways by Dengue virus Curr. Opin. Microbiol. 14 2011 470 475
42. C.V. Fletcher, S.P. Kawle, T.N. Kakuda, P.L. Anderson, D. Weller, L.R. Bushman, R.C. Brundage, and R.P. Remmel Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons AIDS 14 2000 2137 2144
43. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, R.A. Fridell, M.H. Serrano-Wu, D.R. Langley, J.H. Sun, D.R. O'Boyle 2nd, J.A. Lemm, C. Wang, J.O. Knipe, C. Chien, R.J. Colonno, D.M. Grasela, N.A. Meanwell, and L.G. Hamann Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
44. W.Y. Gao, T. Shirasaka, D.G. Johns, S. Broder, and H. Mitsuya Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells J. Clin. Investig. 91 1993 2326 2333
45. J.G. Garcia-Lerma, W. Aung, M.E. Cong, Q. Zheng, A.S. Youngpairoj, J. Mitchell, A. Holder, A. Martin, S. Kuklenyik, W. Luo, C.Y. Lin, D.L. Hanson, E. Kersh, C.P. Pau, A.S. Ray, J.F. Rooney, W.A. Lee, and W. Heneine Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors J. Virol. 85 2011 6610 6617
46. A.O. Guilarde, M.D. Turchi, J.B. Siqueira Jr., V.C. Feres, B. Rocha, J.E. Levi, V.A. Souza, L.S. Boas, C.S. Pannuti, and C.M. Martelli Dengue and dengue hemorrhagic fever among adults: clinical outcomes related to viremia, serotypes, and antibody response J. Infect. Dis. 197 2008 817 824
47. P. Halfon, and S. Locarnini Hepatitis C virus resistance to protease inhibitors J. Hepatol. 55 2011 192 206
48. Y.M. Hrobowski, R.F. Garry, and S.F. Michael Peptide inhibitors of dengue virus and West Nile virus infectivity Virol. J. 2 2005 49
49. K. Jessie, M.Y. Fong, S. Devi, S.K. Lam, and K.T. Wong Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization J. Infect. Dis. 189 2004 1411 1418
50. T. Kampmann, R. Yennamalli, P. Campbell, M.J. Stoermer, D.P. Fairlie, B. Kobe, and P.R. Young In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses Antiviral Res. 84 2009 234 241
51. R. Kanlaya, S.N. Pattanakitsakul, S. Sinchaikul, S.T. Chen, and V. Thongboonkerd The ubiquitin-proteasome pathway is important for dengue virus infection in primary human endothelial cells J. Proteome Res. 9 2010 4960 4971
52. S.J. Kaptein, T. De Burghgraeve, M. Froeyen, B. Pastorino, M.M. Alen, J.A. Mondotte, P. Herdewijn, M. Jacobs, X. de Lamballerie, D. Schols, A.V. Gamarnik, F. Sztaricskai, and J. Neyts A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro Antimicrob. Agents Chemother. 54 2010 5269 5280
53. M. Krawczyk, A. Stankiewicz-Drogon, A.L. Haenni, and A. Boguszewska-Chachulska Fluorometric assay of hepatitis C virus NS3 helicase activity Methods Mol. Biol. 587 2010 211 221
54. R.J. Kuhn, W. Zhang, M.G. Rossmann, S.V. Pletnev, J. Corver, E. Lenches, C.T. Jones, S. Mukhopadhyay, P.R. Chipman, E.G. Strauss, T.S. Baker, and J.H. Strauss Structure of dengue virus: implications for flavivirus organization, maturation, and fusion Cell 108 2002 717 725
55. B.M. Kummerer, and C.M. Rice Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles J. Virol. 76 2002 4773 4784
56. T. Kuntzen, J. Timm, A. Berical, N. Lennon, A.M. Berlin, S.K. Young, B. Lee, D. Heckerman, J. Carlson, L.L. Reyor, M. Kleyman, C.M. McMahon, C. Birch, J. Schulze Zur Wiesch, T. Ledlie, M. Koehrsen, C. Kodira, A.D. Roberts, G.M. Lauer, H.R. Rosen, F. Bihl, A. Cerny, U. Spengler, Z. Liu, A.Y. Kim, Y. Xing, A. Schneidewind, M.A. Madey, J.F. Fleckenstein, V.M. Park, J.E. Galagan, C. Nusbaum, B.D. Walker, G.V. Lake-Bakaar, E.S. Daar, I.M. Jacobson, E.D. Gomperts, B.R. Edlin, S.M. Donfield, R.T. Chung, A.H. Talal, T. Marion, B.W. Birren, M.R. Henn, and T.M. Allen Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients Hepatology 48 2008 1769 1778
57. H. Lai, D. Dou, S. Aravapalli, T. Teramoto, G.H. Lushington, T.M. Mwania, K.R. Alliston, D.M. Eichhorn, R. Padmanabhan, and W.C. Groutas Design, synthesis and characterization of novel 1,2-benzisothiazol-3(2H)-one and 1,3,4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B/NS3 proteases Bioorg. Med. Chem. 21 2013 102 113
58. H. Lai, G. Sridhar Prasad, and R. Padmanabhan Characterization of 8-hydroxyquinoline derivatives containing aminobenzothiazole as inhibitors of dengue virus type 2 protease in vitro Antiviral Res. 97 2013 74 80
59. J.P. Lalezari, J.J. Eron, M. Carlson, C. Cohen, E. DeJesus, R.C. Arduino, J.E. Gallant, P. Volberding, R.L. Murphy, F. Valentine, E.L. Nelson, P.R. Sista, A. Dusek, and J.M. Kilby A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy AIDS 17 2003 691 698
60. A. Lavie, I. Schlichting, I.R. Vetter, M. Konrad, J. Reinstein, and R.S. Goody The bottleneck in AZT activation Nat. Med. 3 1997 922 924
61. C.J. Lee, H.R. Lin, C.L. Liao, and Y.L. Lin Cholesterol effectively blocks entry of flavivirus J. Virol. 82 2008 6470 6480
62. J. Lescar, D. Luo, T. Xu, A. Sampath, S.P. Lim, B. Canard, and S.G. Vasudevan Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target Antiviral Res. 80 2008 94 101
63. D. Leung, K. Schroder, H. White, N.X. Fang, M.J. Stoermer, G. Abbenante, J.L. Martin, P.R. Young, and D.P. Fairlie Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors J. Biol. Chem. 276 2001 45762 45771
64. J. Li, S.P. Lim, D. Beer, V. Patel, D. Wen, C. Tumanut, D.C. Tully, J.A. Williams, J. Jiricek, J.P. Priestle, J.L. Harris, and S.G. Vasudevan Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries J. Biol. Chem. 280 2005 28766 28774
65. L. Li, S.M. Lok, I.M. Yu, Y. Zhang, R.J. Kuhn, J. Chen, and M.G. Rossmann The flavivirus precursor membrane-envelope protein complex: structure and maturation Science 319 2008 1830 1834
66. M. Liao, and M. Kielian Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion J. Cell. Biol. 171 2005 111 120
67. D.H. Libraty, T.P. Endy, H.S. Houng, S. Green, S. Kalayanarooj, S. Suntayakorn, W. Chansiriwongs, D.W. Vaughn, A. Nisalak, F.A. Ennis, and A.L. Rothman Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections J. Infect. Dis. 185 2002 1213 1221
68. D.H. Libraty, P.R. Young, D. Pickering, T.P. Endy, S. Kalayanarooj, S. Green, D.W. Vaughn, A. Nisalak, F.A. Ennis, and A.L. Rothman High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever J. Infect. Dis. 186 2002 1165 1168
69. S.P. Lim, L.S. Sonntag, C. Noble, S.H. Nilar, R.H. Ng, G. Zou, P. Monaghan, K.Y. Chung, H. Dong, B. Liu, C. Bodenreider, G. Lee, M. Ding, W.L. Chan, G. Wang, Y.L. Jian, A.T. Chao, J. Lescar, Z. Yin, T.R. Vedananda, T.H. Keller, and P.Y. Shi Small molecule inhibitors that selectively block dengue virus methyltransferase J. Biol. Chem. 286 2011 6233 6240
70. S.P. Lim, D. Wen, T.L. Yap, C.K. Yan, J. Lescar, and S.G. Vasudevan A scintillation proximity assay for dengue virus NS5 2′-O-methyltransferase- kinetic and inhibition analyses Antiviral Res. 80 2008 360 369
71. Lim., S.P., Bodenreider, C., Shi, P.Y., 2013. Detection and quantification of flavivirus NS5 methyl-transferase activities. In: Edwin Yunhao Gong (Ed.), Antiviral Methods and Protocols, second Ed., vol. 1030. Springer Protocols, Humana Press.
72. Lindenbach, B.D., Thiel, H.-J., Rice, C.M., 2007. Flaviviridae: the virus and their replication, In: Knipe, D.M., Howley, P.M. (Eds.), Fields Virology, fifth Ed., vol. 1. Lippincott William & Wilkins, Philadelphia, PA, pp. 1101-1152
73. C.A. Lipinski Lead- and drug-like compounds: the rule-of-five revolution Drug Discov. Today Technol. 1 2004 337 341
74. W.J. Liu, H.B. Chen, and A.A. Khromykh Molecular and functional analyses of Kunjin virus infectious cDNA clones demonstrate the essential roles for NS2A in virus assembly and for a nonconservative residue in NS3 in RNA replication J. Virol. 77 2003 7804 7813
75. S.M. Lok, J.M. Costin, Y.M. Hrobowski, A.R. Hoffmann, D.K. Rowe, P. Kukkaro, H. Holdaway, P. Chipman, K.A. Fontaine, M.R. Holbrook, R.F. Garry, V. Kostyuchenko, W.C. Wimley, S. Isern, M.G. Rossmann, and S.F. Michael Release of dengue virus genome induced by a peptide inhibitor PLoS One 7 2012 e50995
76. J.G. Low, E.E. Ooi, T. Tolfvenstam, Y.S. Leo, M.L. Hibberd, L.C. Ng, Y.L. Lai, G.S. Yap, C.S. Li, S.G. Vasudevan, and A. Ong Early Dengue infection and outcome study (EDEN) - study design and preliminary findings Ann. Acad. Med. Singapore 35 11 2006 783 789
77. D. Luo, T. Xu, C. Hunke, G. Gruber, S. Vasudevan, and J. Lescar Crystal structure of the NS3 protease-helicase from Dengue virus J. Virol. 82 1 2008 173 183
78. D. Luo, T. Xu, R.P. Watson, D. Scherer-Becker, A. Sampath, W. Jahnke, S.S. Yeong, C.H. Wang, S.P. Lim, A. Strongin, S.G. Vasudevan, and J. Lescar Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein EMBO J. 27 2008 3209 3219
79. L. Ma, C.T. Jones, T.D. Groesch, R.J. Kuhn, and C.B. Post Solution structure of dengue virus capsid protein reveals another fold Proc. Natl. Acad. Sci. U.S.A. 101 2004 3414 3419
80. L. Ma, C.T. Jones, T.D. Groesch, R.J. Kuhn, and C.B. Post Solution structure of dengue virus capsid protein reveals another fold Proc. Natl. Acad. Sci. U.S.A. 101 2004 3414 3419
81. H. Malet, M.P. Egloff, B. Selisko, R.E. Butcher, P.J. Wright, M. Roberts, A. Gruez, G. Sulzenbacher, C. Vonrhein, G. Bricogne, J.M. Mackenzie, A.A. Khromykh, A.D. Davidson, and B. Canard Crystal structure of the RNA polymerase domain of the West Nile virus non-structural protein 5 J. Biol. Chem. 282 2007 10678 10689
82. H. Malet, N. Masse, B. Selisko, J.L. Romette, K. Alvarez, J.C. Guillemot, H. Tolou, T.L. Yap, S. Vasudevan, J. Lescar, and B. Canard The flavivirus polymerase as a target for drug discovery Antiviral Res. 80 2008 23 35
83. E. Mastrangelo, M. Pezzullo, T. De Burghgraeve, S. Kaptein, B. Pastorino, K. Dallmeier, X. de Lamballerie, J. Neyts, A.M. Hanson, D.N. Frick, M. Bolognesi, and M. Milani Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug J. Antimicrob. Chemother. 67 2012 1884 1894
84. C. McGuigan, K. Madela, M. Aljarah, A. Gilles, A. Brancale, N. Zonta, S. Chamberlain, J. Vernachio, J. Hutchins, A. Hall, B. Ames, E. Gorovits, B. Ganguly, A. Kolykhalov, J. Wang, J. Muhammad, J.M. Patti, and G. Henson Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus Bioorg. Med. Chem. Lett. 20 2010 4850 4854
85. G. Melagraki, and A. Afantitis Ligand and structure based virtual screening strategies for hit-finding and optimization of hepatitis C virus (HCV) inhibitors Curr. Med. Chem. 18 2011 2612 2619
86. G. Migliaccio, J.E. Tomassini, S.S. Carroll, L. Tomei, S. Altamura, B. Bhat, L. Bartholomew, M.R. Bosserman, A. Ceccacci, L.F. Colwell, R. Cortese, R. De Francesco, A.B. Eldrup, K.L. Getty, X.S. Hou, R.L. LaFemina, S.W. Ludmerer, M. MacCoss, D.R. McMasters, M.W. Stahlhut, D.B. Olsen, D.J. Hazuda, and O.A. Flores Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro J. Biol. Chem. 278 2003 49164 49170
87. J.L. Miller, R. Lachica, A.C. Sayce, J.P. Williams, M. Bapat, R. Dwek, P.R. Beatty, E. Harris, and N. Zitzmann Liposome-mediated delivery of iminosugars enhances efficacy against dengue virus in vivo Antimicrob. Agents Chemother. 56 2012 6379 6386
88. S. Miller, S. Kastner, J. Krijnse-Locker, S. Buhler, and R. Bartenschlager The non-structural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner J. Biol. Chem. 282 2007 8873 8882
89. S. Miller, S. Sparacio, and R. Bartenschlager Subcellular localization and membrane topology of the dengue virus type 2 non-structural protein 4B J. Biol. Chem. 281 2006 8854 8863
90. Y. Modis, S. Ogata, D. Clements, and S.C. Harrison A ligand-binding pocket in the dengue virus envelope glycoprotein Proc. Natl. Acad. Sci. U.S.A. 100 2003 6986 6991
91. Y. Modis, S. Ogata, D. Clements, and S.C. Harrison Structure of the dengue virus envelope protein after membrane fusion Nature 427 2004 313 319
92. S. Mukhopadhyay, R.J. Kuhn, and M.G. Rossmann A structural perspective of the flavivirus life cycle Nat. Rev. Microbiol. 3 2005 13 22
93. J.L. Munoz-Jordan, G.G. Sanchez-Burgos, M. Laurent-Rolle, and A. Garcia-Sastre Inhibition of interferon signaling by dengue virus Proc. Natl. Acad. Sci. U.S.A. 100 2003 14333 14338
94. D.R. Nelson, S. Zeuzem, P. Andreone, P. Ferenci, R. Herring, D.M. Jensen, P. Marcellin, P.J. Pockros, M. Rodriguez-Torres, L. Rossaro, V.K. Rustgi, T. Sepe, M. Sulkowski, I.R. Thomason, E.M. Yoshida, A. Chan, and G. Hill Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients Ann. Hepatol. 11 2012 15 31
95. C.Y. Ng, F. Gu, W.Y. Phong, Y.L. Chen, S.P. Lim, A. Davidson, and S.G. Vasudevan Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing Antiviral Res. 76 2007 222 231
96. N.M. Nguyen, C.N. Tran, L.K. Phung, K.T. Duong, A. Huynh Hle, J. Farrar, Q.T. Nguyen, H.T. Tran, C.V. Nguyen, L. Merson, L.T. Hoang, M.L. Hibberd, P.P. Aw, A. Wilm, N. Nagarajan, D.T. Nguyen, M.P. Pham, T.T. Nguyen, H. Javanbakht, K. Klumpp, J. Hammond, R. Petric, M. Wolbers, C.T. Nguyen, and C.P. Simmons A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients J. Infect. Dis. 207 2013 1442 1450
97. C.O. Nicholson, J.M. Costin, D.K. Rowe, L. Lin, E. Jenwitheesuk, R. Samudrala, S. Isern, and S.F. Michael Viral entry inhibitors block dengue antibody-dependent enhancement in vitro Antiviral Res. 89 2011 71 74
98. C. Nitsche, M.A. Behnam, C. Steuer, and C.D. Klein Retro peptide-hybrids as selective inhibitors of the Dengue virus NS2B-NS3 protease Antiviral Res. 94 2012 72 79
99. C. Niu, T. Tolstykh, H. Bao, Y. Park, D. Babusis, A.M. Lam, S. Bansal, J. Du, W. Chang, P.G. Reddy, M. Martínez-Gutierrez, J.E. Castellanos, and J.C. Gallego-Gómez Statins reduce dengue virus production via decreased virion assembly Intervirology 54 2011 202 216
100. P. Niyomrattanakit, S.N. Abas, C.C. Lim, D. Beer, P.Y. Shi, and Y.L. Chen A fluorescence-based alkaline phosphatase-coupled polymerase assay for identification of inhibitors of dengue virus RNA-dependent RNA polymerase J. Biomol. Screen. 16 2010 201 210
101. P. Niyomrattanakit, Y.L. Chen, H. Dong, Z. Yin, M. Qing, J.F. Glickman, K. Lin, D. Mueller, H. Voshol, J.Y. Lim, S. Nilar, T.H. Keller, and P.Y. Shi Inhibition of dengue virus polymerase by blocking of the RNA tunnel J. Virol. 84 2010 5678 5686
102. C.G. Noble, Y.L. Chen, H. Dong, F. Gu, S.P. Lim, W. Schul, Q.Y. Wang, and P.Y. Shi Strategies for development of Dengue virus inhibitors Antiviral Res. 85 2010 450 462
103. C.G. Noble, S.P. Lim, Y.L. Chen, C.W. Liew, L. Yap, J. Lescar, and P.Y. Shi Conformational flexibility of the Dengue virus RNA-dependent RNA polymerase revealed by a complex with an inhibitor J. Virol. 87 2013 5291 5295
104. C.G. Noble, C.C. Seh, A.T. Chao, and P.Y. Shi Ligand-bound structures of the dengue virus protease reveal the active conformation J. Virol. 86 2012 438 446
105. C.G. Noble, and P.Y. Shi Structural biology of dengue virus enzymes: towards rational design of therapeutics Antiviral Res. 96 2012 115 126
106. S. Noisakran, N. Onlamoon, P. Songprakhon, H.M. Hsiao, K. Chokephaibulkit, and G.C. Perng Cells in dengue virus infection in vivo Advan. Virol. 2010 2010 164878
107. A.O. Noueiry, P.D. Olivo, U. Slomczynska, Y. Zhou, B. Buscher, B. Geiss, M. Engle, R.M. Roth, K.M. Chung, M. Samuel, and M.S. Diamond Identification of novel small-molecule inhibitors of West Nile virus infection J. Virol. 81 2007 11992 12004
108. Novartis Foundation Symposium 277. 2006. In: Bock, G., Goode, J. (Eds.), New Treatment Strategies for Dengue and Other Flaviviral Diseases. John Wiley and Sons Ltd.
109. C.G. Patkar, M. Larsen, M. Owston, J.L. Smith, and R.J. Kuhn Identification of inhibitors of yellow fever virus replication using a replicon-based high-throughput assay Antimicrob. Agents Chemother. 53 2009 4103 4114
110. R. Perera, and R.J. Kuhn Structural proteomics of dengue virus Curr. Opin. Microbiol. 11 2008 369 377
111. P.J. Pockros Drugs in development for chronic hepatitis C: a promising future Exp. Opin. Biol. Ther. 11 2011 1611 1622
112. P.J. Pockros Non-nucleoside analogue polymerase inhibitors in development Clin. Liver Dis. 17 2013 123 128
113. M.K. Poh, A. Yip, S. Zhang, J.M. Smit, J. Wilschut, J.P. Priestle, P.-Y. S, M.R. Wenka, and W. Schul A small molecule fusion inhibitor of dengue virus Antiviral Res. 84 2009 260 266
114. P. Pugach, T.J. Ketas, E. Michael, and J.P. Moore Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors Virology 377 2008 401 407
115. X. Puyang, D.L. Poulin, J.E. Mathy, L.J. Anderson, S. Ma, Z. Fang, S. Zhu, K. Lin, R. Fujimoto, T. Compton, and B. Wiedmann Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors Antimicrob. Agents Chemother. 54 2010 1981 1987
116. M. Qing, W. Liu, Z. Yuan, F. Gu, and P.Y. Shi A high-throughput assay using dengue-1 virus-like particles for drug discovery Antiviral Res. 86 2010 163 171
117. A.P. Rathore, P.N. Paradkar, S. Watanabe, K.H. Tan, C. Sung, J.E. Connolly, J. Low, E.E. Ooi, and S.G. Vasudevan Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model Antiviral Res. 92 2011 453 460
118. D. Ray, A. Shah, M. Tilgner, Y. Guo, Y. Zhao, H. Dong, T. Deas, Y. Zhou, H. Li, and P.-Y. Shi West nile virus 5′-cap structure is formed by sequential guanine N-7 and ribose 2′-O methylations by nonstructural protein 5 J. Virol. 80 2006 8362 8370
119. F.A. Rey, F.X. Heinz, C. Mandl, C. Kunz, and S.C. Harrison The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution Nature 375 1995 291 298
120. L. Rosen, M.T. Drouet, and V. Deubel Detection of dengue virus RNA by reverse transcription-polymerase chain reaction in the liver and lymphoid organs but not in the brain in fatal human infection Am. J. Trop. Med. Hyg. 61 1999 720 724
121. H. Roth, M. McPherson, P. Hamedani, W.M. Herrmann, E. Sidarous, M. Frampton, J. Maddern, and A. Dieterich Phase I tolerance and pharmacokinetics of a new castanospermine derivative, MDL 28,574A Int. Conf. AIDS 11 1996 2117
122. A.L. Rothman Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms Nat. Rev. Immunol. 11 2011 532 543
123. C. Rothwell, A. Lebreton, C.Y. Ng, J.Y. Lim, W. Liu, S. Vasudevan, M. Labow, F. Gu, and L.A. Gaither Cholesterol biosynthesis modulation regulates dengue viral replication Virology 389 2009 8 19
124. L.M. Schang First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy Exp. Rev. Anti-infect. Ther. 4 2006 953 956
125. A.G. Schmidt, K. Lee, P.L. Yang, and S.C. Harrison Small-molecule inhibitors of dengue-virus entry PLoS Pathog. 8 2012 e1002627
126. A.G. Schmidt, P.L. Yang, and S.C. Harrison Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate PLoS Pathog. 6 2010 e1000851
127. A.G. Schmidt, P.L. Yang, and S.C. Harrison Peptide inhibitors of flavivirus entry derived from the E protein stem J. Virol. 84 2010 12549 12554
128. M.J. Schreiber, E.C. Holmes, S.H. Ong, H.S. Soh, W. Liu, L. Tanner, P.P. Aw, H.C. Tan, L.C. Ng, Y.S. Leo, J.G. Low, A. Ong, E.E. Ooi, S.G. Vasudevan, and M.L. Hibberd Genomic epidemiology of a dengue virus epidemic in urban Singapore J. Virol. 83 2009 4163 4173
129. W. Schul, W. Liu, H.Y. Xu, M. Flamand, and S.G. Vasudevan A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs J. Infect. Dis. 195 2007 665 674
130. Schwegmann, A., Brombacher, F., 2008. Host-directed drug targeting of factors hijacked by pathogens. Sci. Signaling 1, re8.
131. D.E. Scott, A.G. Coyne, S.A. Hudson, and C. Abell Fragment-based approaches in drug discovery and chemical biology Biochemistry 51 2012 4990 5003
132. O.M. Sessions, N.J. Barrows, J.A. Souza-Neto, T.J. Robinson, C.L. Hershey, M.A. Rodgers, J.L. Ramirez, G. Dimopoulos, P.L. Yang, J.L. Pearson, and M.A. Garcia-Blanco Discovery of insect and human dengue virus host factors Nature 458 2009 1047 1050
133. W.R. Shadrick, J. Ndjomou, R. Kolli, S. Mukherjee, A.M. Hanson, and D.N. Frick Discovering new medicines targeting helicases: challenges and recent progress J. Biomol. Screen. 2013
134. M.J. Sofia, W. Chang, P.A. Furman, R.T. Mosley, and B.S. Ross Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase J. Med. Chem. 55 2012 2481 2531
135. A.L. St John, S.N. Abraham, and D.J. Gubler Barriers to preclinical investigations of anti-dengue immunity and dengue pathogenesis Nat. Rev. Microbiol. 11 2013 420 426
136. D.S. Stein, and K.H. Moore Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians Pharmacotherapy 21 2001 11 34
137. C. Steuer, C. Gege, W. Fischl, K.H. Heinonen, R. Bartenschlager, and C.D. Klein Synthesis and biological evaluation of alpha-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture Bioorg. Med. Chem. 19 2011 4067 4074
138. D.T. Tam, T.V. Ngoc, N.T. Tien, N.T. Kieu, T.T. Thuy, L.T. Thanh, C.T. Tam, N.T. Truong, N.T. Dung, P.T. Qui, T.T. Hien, J.J. Farrar, C.P. Simmons, M. Wolbers, and B.A. Wills Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial Clin. Infect. Dis. 55 2012 1216 1224
139. S.L. Tan, G. Ganji, B. Paeper, S. Proll, and M.G. Katze Systems biology and the host response to viral infection Nat. Biotechnol. 25 2007 1383 1389
140. L. Tanner, M. Schreiber, J.G. Low, A. Ong, T. Tolfvenstam, Y.L. Lai, L.C. Ng, Y.S. Leo, L. Thi Puong, S.G. Vasudevan, C.P. Simmons, M.L. Hibberd, and E.E. Ooi Decision tree algorithms predict the diagnosis and outcome of dengue fever in the early phase of illness PLoS Negl. Trop. Dis. 2 3 2008 e196
141. S.M. Tomlinson, R.D. Malmstrom, A. Russo, N. Mueller, Y.P. Pang, and S.J. Watowich Structure-based discovery of dengue virus protease inhibitors Antiviral Res. 82 2009 110 114
142. S.M. Tomlinson, R.D. Malmstrom, and S.J. Watowich New approaches to structure-based discovery of dengue protease inhibitors Infect. Disord. Drug Targets 9 2009 327 343
143. S.M. Tomlinson, and S.J. Watowich Anthracene-based inhibitors of dengue virus NS2B-NS3 protease Antiviral Res. 89 2011 127 135
144. S.M. Tomlinson, and S.J. Watowich Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors Antiviral Res. 93 2012 245 252
145. I. Umareddy, A. Chao, A. Sampath, F. Gu, and S.G. Vasudevan Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA J. Gen. Virol. 87 2006 2605 2614
146. I. Umareddy, O. Pluquet, Q.Y. Wang, S.G. Vasudevan, E. Chevet, and F. Gu Dengue virus serotype infection specifies the activation of the unfolded protein response Virol. J. 4 2007 91
147. E.C. van Gorp, C. Suharti, A.T. Mairuhu, W.M. Dolmans, J. van Der Ven, P.N. Demacker, and J.W. van Der Meer Changes in the plasma lipid profile as a potential predictor of clinical outcome in dengue hemorrhagic fever Clin. Infect. Dis. 34 2002 1150 1153
148. G.J. Veal, M.G. Barry, S.H. Khoo, and D.J. Back In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy AIDS Res. Hum. Retrovir. 13 1997 481 484
149. H.J. Verheij Leadlikeness and structural diversity of synthetic screening libraries Mol. Divers 10 2006 377 388
150. L.A. Villar-Centeno, F.A. Díaz-Quijano, and R.A. Martínez-Vega Biochemical alterations as markers of dengue hemorrhagic fever Am. J. Trop. Med. Hyg. 78 2008 370 374
151. T. Volz, L. Allweiss, M.B. MB, M. Warlich, A.W. Lohse, J.M. Pollok, A. Alexandrov, S. Urban, J. Petersen, M. Lutgehetmann, and M. Dandri The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus J. Hepatol. 58 2013 861 867
152. L.H. Wang, J. Begley, R.L. St Claire 3rd, J. Harris, C. Wakeford, and F.S. Rousseau Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection AIDS Res. Hum. Retroviru. 20 2004 1173 1182
153. Q.Y. Wang, S. Bushell, M. Qing, H.Y. Xu, A. Bonavia, S. Nunes, J. Zhou, M.K. Poh, P. Florez de Sessions, P. Niyomrattanakit, H. Dong, K. Hoffmaster, A. Goh, S. Nilar, W. Schul, S. Jones, L. Kramer, T. Compton, and P.Y. Shi Inhibition of dengue virus through suppression of host pyrimidine biosynthesis J. Virol. 85 2011 6548 6556
154. Q.Y. Wang, R.R. Kondreddi, X. Xie, R. Rao, S. Nilar, H.Y. Xu, M. Qing, D. Chang, H. Dong, F. Yokokawa, S.B. Lakshminarayana, A. Goh, W. Schul, L. Kramer, T.H. Keller, and P.Y. Shi A translation inhibitor that suppresses dengue virus in vitro and in vivo Antimicrob. Agents Chemother. 55 2011 4072 4080
155. Q.Y. Wang, S.J. Patel, E. Vangrevelinghe, H.Y. Xu, R. Rao, D. Jaber, W. Schul, F. Gu, O. Heudi, N.L. Ma, M.K. Poh, W.Y. Phong, T.H. Keller, E. Jacoby, and S.G. Vasudevan A small-molecule dengue virus entry inhibitor Antimicrob. Agents Chemother. 53 2009 1823 1831
156. W.K. Wang, D.Y. Chao, C.L. Kao, H.C. Wu, Y.C. Liu, C.M. Li, S.C. Lin, S.T. Ho, J.H. Huang, and C.C. King High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis Virology 305 2003 330 338
157. W.K. Wang, H.L. Chen, C.F. Yang, S.C. Hsieh, C.C. Juan, S.M. Chang, C.C. Yu, L.H. Lin, J.H. Huang, and C.C. King Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever Clin. Infect. Dis. 43 2006 1023 1030
158. S. Watanabe, A.P. Rathore, C. Sung, F. Lu, Y.M. Khoo, J. Connolly, J. Low, E.E. Ooi, H.S. Lee, and S.G. Vasudevan Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial Antiviral Res. 96 2012 32 35
159. A.M. Wensing, N.M. van Maarseveen, and M. Nijhuis Fifteen years of HIV protease inhibitors: raising the barrier to resistance Antiviral Res. 85 2010 59 74
160. K. Whitby, T. Pierson, B. Geiss, K. Lane, M. Engle, Y. Zhou, R. Doms, and M. Diamond Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo J. Virol. 79 2005 8698 8706
161. J. Winquist, E. Abdurakhmanov, V. Baraznenok, I. Henderson, L. Vrang, and U.H. Danielson Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase Antiviral Res. 97 2013 356 368
162. G. Woo, G. Tomlinson, Y. Nishikawa, M. Kowgier, M. Sherman, D.K. Wong, B. Pham, W.J. Ungar, T.R. Einarson, E.J. Heathcote, and M. Krahn Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses Gastroenterology 139 2010 1218 1229
163. J. Wu, A.K. Bera, R.J. Kuhn, and J.L. Smith Structure of the Flavivirus helicase: implications for catalytic activity, protein interactions, and proteolytic processing J. Virol. 79 2005 10268 10277
164. D.L. Wyles Antiviral resistance and the future landscape of hepatitis C virus infection therapy J. Infect. Dis. 207 Suppl. 1 2013 S33 S39
165. X. Xie, Q.Y. Wang, H.Y. Xu, M. Qing, L. Kramer, Z. Yuan, and P.Y. Shi Inhibition of dengue virus by targeting viral NS4B protein J. Virol. 85 2011 11183 11195
166. S. Xu, H. Li, X. Shao, C. Fan, B. Ericksen, J. Liu, C. Chi, and C. Wang Critical effect of peptide cyclization on the potency of peptide inhibitors against Dengue virus NS2B-NS3 protease J. Med. Chem. 55 2012 6881 6887
167. T. Xu, A. Sampath, A. Chao, D. Wen, M. Nanao, P. Chene, S. Vasudevan, and J. Lescar Structure of the Dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4 A J. Virol. 79 2005 10278 10288
168. T. Yamashita, H. Unno, Y. Mori, H. Tani, K. Moriishi, A. Takamizawa, M. Agoh, T. Tsukihara, and Y. Matsuura Crystal structure of the catalytic domain of Japanese encephalitis virus NS3 helicase/nucleoside triphosphatase at a resolution of 1.8 A Virology 373 2008 426 436
169. C.C. Yang, Y.C. Hsieh, S.J. Lee, S.H. Wu, C.L. Liao, C.H. Tsao, Y.S. Chao, J.H. Chern, C.P. Wu, and A. Yueh Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay Antimicrob. Agents Chemother. 55 2011 229 238
170. T. Yap, T. Xu, Y. Chen, H. Malet, M. Egloff, B. Canard, S. Vasudevan, and J. Lescar Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85-angstrom resolution J. Virol. 81 2007 4753 4765
171. Z. Yin, Y.L. Chen, R.R. Kondreddi, W.L. Chan, G. Wang, R.H. Ng, J.Y. Lim, W.Y. Lee, D.A. Jeyaraj, P. Niyomrattanakit, D. Wen, A. Chao, J.F. Glickman, H. Voshol, D. Mueller, C. Spanka, S. Dressler, S. Nilar, S.G. Vasudevan, P.Y. Shi, and T.H. Keller N-sulfonylanthranilic acid derivatives as allosteric inhibitors of dengue viral RNA-dependent RNA polymerase J. Med. Chem. 52 2009 7934 7937
172. Z. Yin, Y.L. Chen, W. Schul, Q.Y. Wang, F. Gu, J. Duraiswamy, R.R. Kondreddi, P. Niyomrattanakit, S.B. Lakshminarayana, A. Goh, H.Y. Xu, W. Liu, B. Liu, J.Y. Lim, C.Y. Ng, M. Qing, C.C. Lim, A. Yip, G. Wang, W.L. Chan, H.P. Tan, K. Lin, B. Zhang, G. Zou, K.A. Bernard, C. Garrett, K. Beltz, M. Dong, M. Weaver, H. He, A. Pichota, V. Dartois, T.H. Keller, and P.Y. Shi An adenosine nucleoside inhibitor of dengue virus Proc. Natl. Acad. Sci. U.S.A. 106 2009 20435 20439
173. Z. Yin, S.J. Patel, W.L. Wang, W.L. Chan, K.R. Ranga Rao, G. Wang, X. Ngew, V. Patel, D. Beer, J.E. Knox, N.L. Ma, C. Ehrhardt, S.P. Lim, S.G. Vasudevan, and T.H. Keller Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors Bioorg. Med. Chem. Lett. 16 2006 40 43
174. W. Yu, T. Gill, L. Wang, Y. Du, H. Ye, X. Qu, J.T. Guo, A. Cuconati, K. Zhao, T.M. Block, X. Xu, and J. Chang Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection J. Med. Chem. 55 2012 6061 6075
175. X.J. Zhou, K. Pietropaolo, J. Chen, S. Khan, J. Sullivan-Bolyai, and D. Mayers Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects Antimicrob. Agents Chemother. 55 2011 76 81
176. Y. Zhou, D. Ray, Y. Zhao, H. Dong, S. Ren, Z. Li, Y. Guo, K. Bernard, P.-Y. Shi, and H. Li Structure and function of flavivirus NS5 methyltransferase J. Virol. 81 2007 3891 3903
177. Z. Zhou, M. Khaliq, J.E. Suk, C. Patkar, L. Li, R.J. Kuhn, and C.B. Post Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein ACS Chem. Biol. 3 2008 765 775
178. G. Zou, Y.L. Chen, H. Dong, C.C. Lim, L.J. Yap, Y.H. Yau, S.G. Shochat, J. Lescar, and P.Y. Shi Functional analysis of two cavities in flavivirus NS5 polymerase J. Biol. Chem. 286 2011 14362 14372
179. G. Zou, F. Puig-Basagoiti, B. Zhang, M. Qing, L. Chen, K. Pankiewicz, K. Felczak, Z. Yuan, and P. Shi A single-amino acid substitution in West Nile virus 2K peptide between NS4A and NS4B confers resistance to lycorine, a flavivirus inhibitor Virology 384 2008 242 252